Trials

DurSab - Stereotactic Ablative Body Radiotherapy (SABR) followed by Durvalumab as maintenance treatment in patients with advanced non-small cell lung cancer not progressing after 4 to 6 cycles of first-line conventional chemotherapy

Cancer type: Lung cancer

Phase: I

Principal Investigator: de Petris Luigi

Country: SE

Keywords: Durvalumab, stereotactic radiotherapy, non-small cell lung cancer, Sweden, Stockholm, Karolinska

Status: Open for inclusion